1. Home
  2. IGIC vs AVTX Comparison

IGIC vs AVTX Comparison

Compare IGIC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International General Insurance Holdings Ltd.

IGIC

International General Insurance Holdings Ltd.

HOLD

Current Price

$28.69

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Avalo Therapeutics Inc.

AVTX

Avalo Therapeutics Inc.

HOLD

Current Price

$18.35

Market Cap

956.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGIC
AVTX
Founded
2001
2011
Country
Jordan
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
956.7M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
IGIC
AVTX
Price
$28.69
$18.35
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$28.00
$40.57
AVG Volume (30 Days)
89.1K
1.5M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
5.25%
N/A
EPS Growth
N/A
72.07
EPS
N/A
N/A
Revenue
N/A
$27,813,137.00
Revenue This Year
$0.13
N/A
Revenue Next Year
$2.54
N/A
P/E Ratio
$9.05
N/A
Revenue Growth
N/A
2312.27
52 Week Low
$20.82
$6.21
52 Week High
$28.84
$24.27

Technical Indicators

Market Signals
Indicator
IGIC
AVTX
Relative Strength Index (RSI) 63.36 51.08
Support Level $24.51 $17.32
Resistance Level $28.84 $19.06
Average True Range (ATR) 0.67 1.17
MACD -0.01 -0.22
Stochastic Oscillator 93.10 18.81

Price Performance

Historical Comparison
IGIC
AVTX

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Share on Social Networks: